GSK plc (NYSE:GSK) Position Raised by Marcum Wealth LLC

Marcum Wealth LLC raised its position in shares of GSK plc (NYSE:GSK) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,366 shares of the pharmaceutical company’s stock after purchasing an additional 591 shares during the quarter. Marcum Wealth LLC’s holdings in GSK were worth $317,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Eastern Bank acquired a new stake in shares of GSK in the third quarter valued at $26,000. ST Germain D J Co. Inc. raised its position in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 522 shares in the last quarter. Sunbelt Securities Inc. lifted its holdings in GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. Concord Wealth Partners boosted its position in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC bought a new position in shares of GSK during the 2nd quarter valued at about $37,000. 15.74% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on GSK. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and dropped their target price for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Monday. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Down 1.8 %

GSK stock opened at $32.12 on Wednesday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm has a market capitalization of $66.57 billion, a price-to-earnings ratio of 20.86, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a 50 day moving average price of $34.20 and a 200 day moving average price of $38.08.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.89%. GSK’s payout ratio is currently 95.45%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.